Science and practice of arrhythmogenic cardiomyopathy: A paradigm shift

Authors

  • Mohamed ElMaghawry 1. Aswan Heart Centre, Aswan, Egypt 2. Division of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
  • Federico Migliore Division of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
  • Nazar Mohammed The Heart Hospital, Hamad Medical Corporation, Doha, Qatar
  • Despina Sanoudou Department of Pharmacology, Medical School, University of Athens, Greece
  • Mohammed Alhashemi The Heart Hospital, Hamad Medical Corporation, Doha, Qatar

Abstract

[no abstract - first paragraph of article]

The clinical, genetic, and molecular paradigm of arrhythmogenic right ventricular cardiomyopathy (ARVC) has markedly progressed through the last three decades, shifting from the classical ARVC as a progressive condition characterized by fibrofatty replacement of the right ventricle into a wider spectrum of arrhythmogenic cardiomyopathy (AC), which covers ARVC with its various clinical phases (occult, electric, right heart failure and late stage biventricular heart failure), biventricular arrhythmic cardiomyopathy, left dominant arrhythmic cardiomyopathy, Naxos and Carvajal syndromes. Epidemiologically, the disease was first associated with the Mediterranean basin (mainly Italy and France), however further studies have reported AC in many races and ethnic backgrounds. 

Downloads

Published

2017-04-18

Issue

Vol. 2013 No. 1 (2013)

Section

Review articles

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.